NASDAQ:ADAG Adagene Q4 2025 Earnings Report $3.81 -0.16 (-3.95%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adagene EPS ResultsActual EPS-$0.04Consensus EPS -$0.28Beat/MissBeat by +$0.24One Year Ago EPSN/AAdagene Revenue ResultsActual Revenue$3.84 millionExpected Revenue$17.50 millionBeat/MissMissed by -$13.66 millionYoY Revenue GrowthN/AAdagene Announcement DetailsQuarterQ4 2025Date4/1/2026TimeBefore Market OpensConference Call DateWednesday, April 1, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Adagene Earnings HeadlinesAdagene to Participate in Two Upcoming Investor ConferencesMay 12, 2026 | globenewswire.comAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor TypesApril 17, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 1 at 1:00 AM | InvestorPlace (Ad)Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor TypesApril 17, 2026 | globenewswire.comAdagene Looks Attractive With ADG126 And Validating PartnershipsApril 16, 2026 | seekingalpha.comAdagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardApril 14, 2026 | globenewswire.comSee More Adagene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagene and other key companies, straight to your email. Email Address About AdageneAdagene (NASDAQ:ADAG) Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy. At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials. Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.View Adagene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameMarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
